Yearly Archives: 2016

Knowing that many clinicians find it difficult to correctly diagnose patients with Lewy body dementia, researchers have set out to develop a clinical profile for these patients. Their findings are published in the Journal of Alzheimer’s Disease.

The study compared 21 patients with Lewy body dementia to 21 patients with Alzheimer’s disease and 21 patients with Parkinson’s disease. The patients were carefully matched by age, gender, education, race, degree of cognitive impairment, and degree of motor (physical) impairment. Pairs were compared using cognitive, functional, behavioral and motor measures.

Researchers found that the diagnosis is likely Lewy body dementia if the patient is characterized by a specific cognitive profile (retrieval memory disturbance and deficits in visuospatial and executive domains), along with axial (trunk/body) posture impairments & gait/balance instability. Compared to Alzheimer’s patients, Lewy body dementia patients have more executive and visuospatial deficits and less amnesia and disorientation, and also show more daytime sleepiness, cognitive/behavioral fluctuations, hallucinations and obstructive sleep apnea than either Alzheimer’s or Parkinson’s patients. Significant correlations were noted between axial motor, balance and gait disturbances and executive functioning, visuospatial abilities and global cognitive deficits.

Lewy bodies are collections of proteins (alpha-synuclein) that accumulate abnormally in the brain, that are not typically seen in Alzheimer’s, and are deposited in different parts of the brain than in Parkinson’s. These toxic alpha-synuclein proteins accumulate gradually, impact specific brain regions leading to its unique clinical symptoms and disease course, and need to be treated and managed differently than those with Alzheimer’s or Parkinson’s disease.

Paper: “Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer’s and Parkinson’s Diseases”

Reprinted from materials provided by The Ohio State University.

Researchers have found that the gut may be key to preventing Parkinson’s disease. Cells located in the intestine spark an immune response that protects neurons against damage connected with Parkinson’s disease. Acting like detectives, the immune intestinal cells identify damaged machinery within neurons and discard the defective parts. That action ultimately preserves neurons whose impairment or death is known to cause Parkinson’s. The research was published in the journal Cell Reports.

Scientists have previously linked Parkinson’s to defects in mitochondria, but why and how mitochondrial defects effect neurons remain a mystery. Whatever the answer, damaged mitochondria have been linked to other nervous disorders as well, including ALS and Alzheimer’s.

The research team exposed roundworms to a poison called rotenone, which scientists know kills neurons whose death is linked to Parkinson’s. As expected, the rotenone began damaging the mitochondria in the worms’ neurons. To the researchers’ surprise, though, the damaged mitochondria did not kill all of the worms’ dopamine-producing neurons; in fact, over a series of trials, an average of only seven percent of the worms, roughly 210 out of 3,000, lost dopamine-producing neurons when given the poison.

It turns out that the roundworms’ immune defenses, activated when the rotenone was introduced, discarded many of the defected mitochondria, halting a sequence that would’ve led to the loss of dopamine-producing neurons. Importantly, the immune response originated in the intestine, not the nervous system.

Prevailing theory holds that mitochondria originated independently as a type of bacterium and were only later incorporated into the cells of animal, plants, and fungi as an energy producer. If that theory is correct, the intestinal immune responders may be especially sensitive to changes in mitochondrial function not only for its potential damaging effects, the researchers say, but because of the mitochondria’s ancient and foreign past as well.

Paper: “The Mitochondria-Regulated Immune Pathway Activated in the C. elegans Intestine Is Neuroprotective”

Reprinted from materials provided by the University of Iowa.

In the quest to understand the driving forces behind neurodegenerative diseases, researchers in recent years have zeroed in on clumps of malfunctioning proteins thought to kill neurons in the brain and spinal cord by jamming their cellular machinery. In a new study published in the journal Structure, researchers announced the first evidence that stabilizing a protein called SOD1 can help reverse this process in the types of neurons affected by the fatal neurodegenerative condition Amyotrophic Lateral Sclerosis (ALS). Also known as Lou Gehrig’s disease, ALS has no cure and its causes remain largely mysterious.

In addition to showing that stabilizing SOD1 is protective for motor neuron-like cells, the new study is also the first to demonstrate a way to mutate disease-associated SOD1 in order to stabilize it, offering exciting new leads for finding drugs that could potentially prevent the disease or slow its progression.

The findings could be particularly relevant to a subset of ALS cases – an estimated 1 to 2 percent – that are associated with variations in the SOD1 protein. However, SOD1 has been implicated in toxic clump formation even in patients without mutations in their SOD1 genes, suggesting that stabilizing the protein could benefit many other patients as well.

Paper: “A Phosphomimetic Mutation Stabilizes SOD1 and Rescues Cell Viability in the Context of an ALS-Associated Mutation”

Reprinted from materials provided by UNC Health Care.

Researchers report that they have identified a protein that enables a toxic natural aggregate to spread from cell to cell in a mammal’s brain — and a way to block that protein’s action. Their study in mice and cultured cells suggests that an immunotherapy already in clinical trials as a cancer therapy should also be tested as a way to slow the progress of Parkinson’s disease, the researchers say.

A report on the study appears in the journal Science.

According to the researchers, the new findings hinge on how aggregates of α-synuclein protein enter brain cells. Abnormal clumps of α-synuclein protein are often found in autopsies of people with Parkinson’s disease and are thought to cause the death of dopamine-producing brain cells.

A few years ago, the researchers say, a researcher in Germany published evidence for a novel theory that Parkinson’s disease progresses as α-synuclein aggregates spread from brain cell to brain cell, inducing previously normal α-synuclein protein to aggregate, and gradually move from the „lower” brain structures responsible for movement and basic functions to „higher” areas associated with processes like memory and reasoning. Intrigued, the researchers began working to investigate how the aggregates enter cells.

The researchers knew they were looking for a certain kind of protein called a transmembrane receptor. They first found a type of cell α-synuclein aggregates could not enter — a line of human brain cancer cells grown in the laboratory. The next step was to add genes for transmembrane receptors one by one to the cells and see whether any of them allowed the aggregates in. Three of the proteins did, and one, LAG3, had a heavy preference for latching on to α-synuclein aggregates over nonclumped α-synuclein.

The team next bred mice that lacked the gene for LAG3 and injected them with α-synuclein aggregates. „Typical mice develop Parkinson’s-like symptoms soon after they’re injected, and within six months, half of their dopamine-making neurons die,” said Ted Dawson, one of the study’s leaders. „But mice without LAG3 were almost completely protected from these effects.” Antibodies that blocked LAG3 had similar protective effects in cultured neurons, the researchers found.

The researchers note that antibodies targeting LAG3 are already in clinical trials to test whether they can beef up the immune system during chemotherapy. If those trials demonstrate the drugs’ safety, the process of testing them as therapeutics for Parkinsons’ disease might be sped up, they say.

For now, the research team is planning to continue testing LAG3 antibodies in mice and to further explore LAG3’s function.

Paper: “Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3”
Reprinted from materials provided by Johns Hopkins University.

Researchers have identified a potential treatment to delay motor neuron loss and symptoms in the inevitably fatal motor neuron disease (MND).

Researchers said triheptanoin, a synthetic triglyceride oil, might help to address problems with energy metabolism associated with the neurodegenerative disease.

The research, published in PLOS ONE, tested if giving oral triheptanoin could prevent cell death and symptom onset in an animal model of MND.

“We found that motor neuron loss was reduced by a third and loss of limb strength and body weight were delayed,” said Dr Karin Borge, one of the authors of the study. “Our data showed an improvement in disease symptoms when treatment was initiated prior to their onset. This raises hope that triheptanoin may be able to preserve motor neuron and muscle function when treatment is started at an early stage of the disease.”

Paper: “Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis”

Reprinted from materials provided by the University of Queensland.